New Delhi, July 31 -- An uptick in Sun Pharmaceutical Industries Ltd's domestic business and robust growth in its global specialty business are expected to boost the company's earnings for the June quarter.

India's largest drugmaker, which has posted steady mid-to-high single-digit growth for eight consecutive quarters, is expected to see its first-quarter revenue increase 7-8% year-on-year, according to brokerages Nuvama and Kotak Securities.

Sun Pharma is set to post its financial results for the first quarter on Thursday, 31 June.

Its US generics business is expected to see sequentially higher sales of 3-5%, aided by a quarter-on-quarter increase in specialty sales, and higher sales of blood cancer drug Revlimid, which is expected t...